EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Remimazolam attenuates lipopolysaccharide-induced neuroinflammation and cognitive dysfunction

Leguang Zhou, Hongzhao Shi, Mengzhe Xiao, Wenjie Liu, Lijuan Wang, Shangtao Zhou, Shenghua Chen, Yan Wang, Chengxi Liu

Behavioural Brain Research · 2025

DOI: 10.1016/j.bbr.2024.115268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Behavioural Brain Research, 2025. Verfasst von Leguang Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Second Affiliated Hospital of University of South China, Hengyang, China; University of South China Hengyang Medica…. Hauptthemen laut MEDLINE: Lipopolysaccharides, Cognitive Dysfunction, Neuroinflammatory Diseases, Mice, Inbred C57BL. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Remimazolam, a novel benzodiazepine, is widely used as an anesthetic in endoscopic procedures; however, its effects on cognitive function remain unclear, limiting its broader application in general anaesthesia. Neuroinflammation is a well-established key factor in the etiology and progression of cognitive dysfunction, including conditions such as Alzheimer's disease, Parkinson's disease, postoperative delirium, and postoperative cognitive dysfunction. Preclinical studies have demonstrated that remimazolam exerts anti-inflammatory and neuroprotective effects, and clinical reports indicate a reduced incidence of postoperative delirium in patients treated with remimazolam. Nevertheless, whether remimazolam improves cognitive function through its anti-inflammatory properties remains uncertain. This study aimed to investigate the neuroprotective effects of remimazolam and its underlying mechanism in a lipopolysaccharide (LPS)-induced model of neuroinflammation, neuronal injury, and cognitive dysfunction METHODS: C57BL/6 J male mice were administered LPS intraperitoneally to establish a model of neuroinflammation-induced cognitive impairment. A subset of mice received remimazolam via intraperitoneal injection 30 minutes prior to LPS administration. Cognitive performance was evaluated using behavioural tests, including the Morris Water Maze (MWM), Novel Object Recognition (NOR) test, and Open Field Test (OFT). Hippocampal tissues were analyzed by haematoxylin-eosin (HE) staining to assess structural changes. Inflammatory markers, including Interleukin (IL)-6, IL-1β, and tumor necrosis factor-α, were quantified using enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR. Immunofluorescence was used to detect translocator protein (TSPO) and markers of microglia activation (IBA-1, CD16/32, and CD206). RESULTS: (1) Remimazolam reversed LPS-induced cognitive deficits, as evidenced by shorter spatial exploration latency and increased platform crossings in the MWM, and an elevated recognition index in the NOR test. (2) Remimazolam improved hippocampal morphology, reducing LPS-induced neuronal damage. (3) Remimazolam significantly decreased levels of hippocampal inflammatory cytokines, inhibited microglial activation, promoted M2-type microglia polarization, and increased TSPO expression. CONCLUSION: Remimazolam demonstrated neuroprotective and anti-neuroinflammatory effects in a mouse model of LPS-induced cognitive impairment. These effects are likely mediated through the regulation of TSPO, which inhibits microglial activation and promotes the polarization of microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipopolysaccharidesCognitive DysfunctionNeuroinflammatory DiseasesMice, Inbred C57BLNeuroprotective AgentsBenzodiazepinesDisease Models, AnimalAnimalsMaleMiceHippocampusAnti-Inflammatory AgentsMicrogliaCytokinesBehavior, Animal

Stichwörter der Autor:innen

Cognitive functionMicrogliaNeuroinflammationRemimazolamTranslocator protein

Substanzen

LipopolysaccharidesNeuroprotective AgentsremimazolamBenzodiazepinesAnti-Inflammatory AgentsCytokines

Autor:innen und Institutionen

  • Department of Anesthesiology, The Second Affiliated Hospital of University of South China, Hengyang, China; University of South China Hengyang Medical School Clinical Anatomy & Reproductive Medicine Application Institut…
  • Department of Anesthesiology, The Second Affiliated Hospital of University of South China, Hengyang, China.
  • University of South China Hengyang Medical School Clinical Anatomy & Reproductive Medicine Application Institute, China.
  • Department of Anesthesiology, The Second Affiliated Hospital of University of South China, Hengyang, China. Electronic address: 1609779291@qq.com.
  • Department of Anesthesiology, The Second Affiliated Hospital of University of South China, Hengyang, China; Key Laboratory of Anesthesiology and Resuscitation (Huazhong University of Science and Technology), Ministry of…

Zitieren

APA

Zhou, L., Shi, H., Xiao, M., Liu, W., Wang, L., Zhou, S., Chen, S., Wang, Y., & Liu, C. (2025). Remimazolam attenuates lipopolysaccharide-induced neuroinflammation and cognitive dysfunction. Behavioural Brain Research. https://doi.org/10.1016/j.bbr.2024.115268

Vancouver

Zhou L, Shi H, Xiao M, Liu W, Wang L, Zhou S, et al. Remimazolam attenuates lipopolysaccharide-induced neuroinflammation and cognitive dysfunction. Behavioural Brain Research. 2025. doi:10.1016/j.bbr.2024.115268

BibTeX
@article{Zhou2025,
  author = {Zhou, Leguang and Shi, Hongzhao and Xiao, Mengzhe and Liu, Wenjie and Wang, Lijuan and Zhou, Shangtao and Chen, Shenghua and Wang, Yan and Liu, Chengxi},
  title = {Remimazolam attenuates lipopolysaccharide-induced neuroinflammation and cognitive dysfunction},
  journal = {Behavioural Brain Research},
  year = {2025},
  doi = {10.1016/j.bbr.2024.115268}
}
Kostenlos starten →